Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
21,847,524
-
Total 13F shares
-
1,045,307
-
Share change
-
+412,737
-
Total reported value
-
$1,678,185
-
Price per share
-
$1.60
-
Number of holders
-
29
-
Value change
-
+$602,643
-
Number of buys
-
15
-
Number of sells
-
6
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q4 2025
As of 31 Dec 2025,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) was held by
29 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,045,307 shares.
The largest 10 holders included
VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, JANE STREET GROUP, LLC, GSA CAPITAL PARTNERS LLP, BlackRock, Inc., STATE STREET CORP, HighTower Advisors, LLC, UBS Group AG, HRT FINANCIAL LP, and DIVERSIFY WEALTH MANAGEMENT, LLC.
This page lists
29
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.